Table 1 Frequency and proportion of cases of breast cancer recurrence and matched controls within group strata (I) expressing the oestrogen receptor and receiving at least 1 year of tamoxifen therapy (ERP+/TAM+), or (II) not expressing the oestrogen receptor, never receiving tamoxifen therapy, and surviving at least 1 year after diagnosis (ERP−/TAM−)
Group I: ERP+/ TAM+ ( n (%)) | Group II: ERP−/ TAM− ( n (%)) | |||
|---|---|---|---|---|
Cases | Controls | Cases | Controls | |
Citalopram prescription | ||||
Ever | 17 (9) | 21 (11) | 3 (3) | 5 (6) |
Never | 167 (91) | 163 (89) | 84 (97) | 82 (94) |
Other CYP2D6 inhibitors, including other SSRI | ||||
Ever | 48 (26) | 51 (28) | 25 (29) | 17 (20) |
Never | 136 (74) | 133 (72) | 62 (71) | 70 (80) |
Diagnosis year a | ||||
1985–1993 | 33 (18) | 34 (18) | 13 (15) | 11 (13) |
1994–1996 | 32 (17) | 29 (16) | 17 (20) | 18 (21) |
1997–2001 | 119 (65) | 121 (66) | 57 (66) | 58 (67) |
Age at diagnosis | ||||
35–44 | 13 (7) | 11 (6) | 15 (17) | 12 (14) |
45–55 | 38 (21) | 34 (18) | 37 (43) | 29 (33) |
55–65 | 91 (49) | 93 (51) | 26 (30) | 29 (33) |
65–70 | 42 (23) | 46 (25) | 9 (10) | 17 (20) |
Menopausal status at diagnosis a | ||||
Premenopausal | 24 (13) | 24 (13) | 30 (34) | 30 (34) |
Postmenopausal | 160 (87) | 160 (87) | 57 (66) | 57 (66) |
County of residence at diagnosis a | ||||
Aarhus | 70 (38) | 70 (38) | 37 (43) | 37 (43) |
North Jutland | 88 (48) | 88 (48) | 37 (43) | 37 (43) |
Viborg | 15 (8) | 15 (8) | 9 (10) | 9 (10) |
Ringkøbing | 11 (6) | 11 (6) | 4 (5) | 4 (5) |
UICC tumour stage at diagnosis a | ||||
Stage I | 7 (4) | 7 (4) | 4 (5) | 4 (5) |
Stage II | 79 (43) | 79 (43) | 41 (47) | 41 (47) |
Stage III | 98 (53) | 98 (53) | 42 (48) | 42 (48) |
Histological grade | ||||
Grade I | 31 (17) | 33 (18) | 4 (5) | 17 (20) |
Grade II | 73 (40) | 87 (47) | 29 (33) | 2 (2) |
Grade III | 44 (24) | 24 (13) | 38 (44) | 22 (25) |
Missing | 36 (20) | 40 (22) | 16 (18) | 46 (53) |
Surgery type | ||||
Breast conserving surgery | 22 (12) | 22 (12) | 9 (10) | 4 (5) |
Mastectomy | 162 (88) | 162 (88) | 78 (90) | 83 (95) |
Radiation therapy | ||||
Yes | 86 (47) | 79 (43) | 43 (49) | 36 (41) |
No | 98 (53) | 105 (57) | 44 (51) | 51 (59) |
Tamoxifen protocol | ||||
1 year | 57 (31) | 57 (31) | Not applicable | Not applicable |
2 years | 10 (5.4) | 10 (5.4) | ||
5 years | 117 (64) | 117 (64) | ||
Systemic adjuvant chemotherapy | ||||
Yes | 21 (11) | 24 (13) | 70 (80) | 61 (70) |
No | 163 (89) | 160 (87) | 17 (20) | 26 (30) |
